Avigen is a development stage biopharmaceutical company focusing on small molecule therapeutics and biologics to treat neurological and neuromuscular disorders. The company’s current pipeline products primarily address spasticity and neuromuscular spasm and neuropathic pain.

Report Highlights
Avigen’s development programs include AV650 in Phase II trials for spasticity and neuromuscular spasm; AV411 in Phase I trials and AV333 in preclinical for neuropathic pain. Further, in collaboration with University of Colorado Avigen explores the use of AV411 for opioid withdrawal. The company’s revenues increased at a CAGR of 16% during 2002-2006 from $0.057 million to $0.103 million. The increase in revenues was primarily due to the deferred revenues from Bayer in connection with the development of Coagulin-B for the treatment of hemophilia-B. In addition, Avigen received license fee and royalty payments on adeno-associated virus (AAV) technology; and grants from National Institutes of Health (NIH) for exploring the use of AV411 for neuropathic pain, in collaboration with University of Colorado.
[Studien Infos ausblenden]

Table 1: Avigen - Key Facts 6
Table 2: Avigen – Year-End Share Price and Market Capitalization, 2002-2006 ($) 10
Table 3: Avigen - Key Events Impacting Share Price Performance 10
Table 4: Avigen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
Table 5: Avigen - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
Table 6: Avigen - Balance Sheet 14
Table 7: Avigen - Cash Flow 14
Table 8: Avigen - In-house Pipeline Products 15
Table 9: Avigen - Key Competitors 17
Table 10: Avigen - Key Suppliers 18
Table 11: Avigen - Key Clients 18
Table 12: Avigen - Key Shareholders 19
Table 13: Avigen - SWOT Analysis Summary 23
Table 14: Avigen - Value Chain Analysis 28
Table 15: Avigen - Key Employees 30
Table 16: Avigen- Financial and Operational Overview 37
Figure 1: Avigen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
[Tabellenverzeichnis ausblenden]